CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

Barbara Savoldo, Carlos Almeida Ramos, Enli Liu, Martha P. Mims, Michael J. Keating, George Carrum, Rammurti T. Kamble, Catherine M. Bollard, Adrian P. Gee, Zhuyong Mei, Hao Liu, Bambi Grilley, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti

Research output: Contribution to journalArticle

527 Citations (Scopus)

Abstract

Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR + T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR + T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.

Original languageEnglish (US)
Pages (from-to)1822-1826
Number of pages5
JournalJournal of Clinical Investigation
Volume121
Issue number5
DOIs
StatePublished - May 2 2011
Externally publishedYes

Fingerprint

Antigen Receptors
T-Cell Lymphoma
T-Cell Antigen Receptor
T-Lymphocytes
Immunotherapy
CD19 Antigens
Neoplasms
B-Cell Lymphoma
B-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. / Savoldo, Barbara; Ramos, Carlos Almeida; Liu, Enli; Mims, Martha P.; Keating, Michael J.; Carrum, George; Kamble, Rammurti T.; Bollard, Catherine M.; Gee, Adrian P.; Mei, Zhuyong; Liu, Hao; Grilley, Bambi; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.; Dotti, Gianpietro.

In: Journal of Clinical Investigation, Vol. 121, No. 5, 02.05.2011, p. 1822-1826.

Research output: Contribution to journalArticle

Savoldo, B, Ramos, CA, Liu, E, Mims, MP, Keating, MJ, Carrum, G, Kamble, RT, Bollard, CM, Gee, AP, Mei, Z, Liu, H, Grilley, B, Rooney, CM, Heslop, HE, Brenner, MK & Dotti, G 2011, 'CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients', Journal of Clinical Investigation, vol. 121, no. 5, pp. 1822-1826. https://doi.org/10.1172/JCI46110
Savoldo, Barbara ; Ramos, Carlos Almeida ; Liu, Enli ; Mims, Martha P. ; Keating, Michael J. ; Carrum, George ; Kamble, Rammurti T. ; Bollard, Catherine M. ; Gee, Adrian P. ; Mei, Zhuyong ; Liu, Hao ; Grilley, Bambi ; Rooney, Cliona M. ; Heslop, Helen E. ; Brenner, Malcolm K. ; Dotti, Gianpietro. / CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. In: Journal of Clinical Investigation. 2011 ; Vol. 121, No. 5. pp. 1822-1826.
@article{3fcb1a82adf2433aaf7ff0d7beb7c22f,
title = "CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients",
abstract = "Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR + T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR + T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.",
author = "Barbara Savoldo and Ramos, {Carlos Almeida} and Enli Liu and Mims, {Martha P.} and Keating, {Michael J.} and George Carrum and Kamble, {Rammurti T.} and Bollard, {Catherine M.} and Gee, {Adrian P.} and Zhuyong Mei and Hao Liu and Bambi Grilley and Rooney, {Cliona M.} and Heslop, {Helen E.} and Brenner, {Malcolm K.} and Gianpietro Dotti",
year = "2011",
month = "5",
day = "2",
doi = "10.1172/JCI46110",
language = "English (US)",
volume = "121",
pages = "1822--1826",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

AU - Savoldo, Barbara

AU - Ramos, Carlos Almeida

AU - Liu, Enli

AU - Mims, Martha P.

AU - Keating, Michael J.

AU - Carrum, George

AU - Kamble, Rammurti T.

AU - Bollard, Catherine M.

AU - Gee, Adrian P.

AU - Mei, Zhuyong

AU - Liu, Hao

AU - Grilley, Bambi

AU - Rooney, Cliona M.

AU - Heslop, Helen E.

AU - Brenner, Malcolm K.

AU - Dotti, Gianpietro

PY - 2011/5/2

Y1 - 2011/5/2

N2 - Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR + T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR + T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.

AB - Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR + T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR + T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=79955517235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955517235&partnerID=8YFLogxK

U2 - 10.1172/JCI46110

DO - 10.1172/JCI46110

M3 - Article

VL - 121

SP - 1822

EP - 1826

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -